Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

21.11.22	Form 3 875045 (RSS)
10.11.22	Biogen Appoints Christopher Viehbacher As President And CEO (RTTNews)
10.11.22	Biogen Names Christopher Viehbacher President and Chief Executive Officer (GlobeNewswire)
10.11.22	Form 8-K 875045 (RSS)
28.10.22	Form 4 875045 (RSS)
26.10.22	Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS (GlobeNewswire)
26.10.22	New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS (GlobeNewswire)
25.10.22	Biogen Raises 2022 Guidance (RTTNews)
25.10.22	Form 8-K 875045 (RSS)
25.10.22	Form 10-Q 875045 (RSS)
17.10.22	Sage Therapeutics, Biogen Report Further Analyses From Zuranolone Trial In Postpartum Depression (RTTNews)
17.10.22	Biogen: FDA Extends Review Period Of NDA For Tofersen - Quick Facts (RTTNews)
17.10.22	Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen (GlobeNewswire)
13.10.22	SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm (PR Newswire)
30.09.22	Biogen: EMA To Review MAA For BIIB800 - Quick Facts (RTTNews)
30.09.22	Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab) (GlobeNewswire)
28.09.22	Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… (RTTNews)
28.09.22	Biogen And Eisai's Lecanemab Slows Progression Of Alzheimer's Disease In Phase 3 Trial (RTTNews)
28.09.22	LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WI... (PR Newswire)
27.09.22	Biogen Agrees To Pay $900 Mln Over Kickback Allegations (RTTNews)
21.09.22	The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS (GlobeNewswire)
13.09.22	SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm (PR Newswire)
07.09.22	The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus (GlobeNewswire)
04.08.22	EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFE... (PR Newswire)
28.07.22	The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus (GlobeNewswire)
26.07.22	FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS (GlobeNewswire)
21.07.22	ABT Raises Earnings Forecast, BIIB Provides Rosy Revenue Outlook, ELV Q2 Revenue Up 15.6% (RTTNews)
20.07.22	Biogen Boosts FY22 Outlook As Q2 Results Top Estimates (RTTNews)
20.07.22	Current report (RSS)
06.07.22	Post-Effective amendments for registration statement (RSS)
06.07.22	THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY (PR Newswire)
21.06.22	European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) (GlobeNewswire)
15.06.22	New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen) (GlobeNewswire)
06.06.22	Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease (GlobeNewswire)
03.06.22	Biogen, Bio-Thera Presents Positive Phase 3 Data For Tocilizumab Biosimilar In Rheumatoid Arthritis (RTTNews)
03.06.22	Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022) (GlobeNewswire)
03.06.22	Ionis: Tofersen Slows Disease Progression In Phase 3 VALOR Study (RTTNews)
03.06.22	New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS (GlobeNewswire)
17.05.22	Registration of securities, business combinations (RSS)
10.05.22	EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY (PR Newswire)
05.05.22	Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis (GlobeNewswire)
03.05.22	Biogen Reaffirms FY22 Outlook; Q1 Adj. EPS Misses Estimates (RTTNews)
29.04.22	Form DEF 14A 875045 (RSS)
04.04.22	New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression (GlobeNewswire)
30.03.22	Biogen Submits Final Protocol For Envision Trial Of Aduhelm On Alzheimer's Disease (RTTNews)
30.03.22	Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA (GlobeNewswire)
28.03.22	Biogen : Phase 1 Study Of BIIB078 On Amyotrophic Lateral Sclerosis Fails To Meet Secondary Endpoints (RTTNews)
28.03.22	Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis (GlobeNewswire)
28.03.22	Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis (PR Newswire)
22.03.22	LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Starker Wochentag in Frankfurt: DAX bewegt sich zum Ende des Freitagshandels im Plus
22.11.24		Gewinne in Frankfurt: SDAX zum Handelsende freundlich
22.11.24		Gewinne in Frankfurt: LUS-DAX steigt schlussendlich
22.11.24		EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück
22.11.24		DAX-Handel aktuell: DAX nachmittags mit positivem Vorzeichen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Starker Wochentag in Frankfurt: DAX bewegt sich zum Ende des Freitagshandels im Plus

22.11.24

Gewinne in Frankfurt: SDAX zum Handelsende freundlich

22.11.24

Gewinne in Frankfurt: LUS-DAX steigt schlussendlich

22.11.24

EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück

22.11.24

DAX-Handel aktuell: DAX nachmittags mit positivem Vorzeichen